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Introduction: Goal-directed fluid therapy strategies have been shown to benefit moderate- to high-risk surgery
patients. Despite this, these strategies are often not implemented. The aim of this study was to assess a closed-loop
fluid administration system in a surgical cohort and compare the results with those for matched patients who
received manual management. Our hypothesis was that the patients receiving closed-loop assistance would spend
more time in a preload-independent state, defined as percentage of case time with stroke volume variation less
than or equal to 12%.
Methods: Patients eligible for the study were all those over 18 years of age scheduled for hepatobiliary, pancreatic or
splenic surgery and expected to receive intravascular arterial blood pressure monitoring as part of their anesthetic care.
The closed-loop resuscitation target was selected by the primary anesthesia team, and the system was responsible for
implementation of goal-directed fluid therapy during surgery. Following completion of enrollment, each study patient
was matched to a non–closed-loop assisted case performed during the same time period using a propensity match to
reduce bias.
Results: A total of 40 patients were enrolled, 5 were ultimately excluded and 25 matched pairs were selected from
among the remaining 35 patients within the predefined caliper distance. There was no significant difference in
fluid administration between groups. The closed-loop group spent a significantly higher portion of case time in a
preload-independent state (95 ± 6% of case time versus 87 ± 14%, P =0.008). There was no difference in case mean
or final stroke volume index (45 ± 10 versus 43 ± 9 and 45 ± 11 versus 42 ± 11, respectively) or mean arterial pressure
(79 ± 8 versus 83 ± 9). Case end heart rate was significantly lower in the closed-loop assisted group (77 ± 10 versus
88 ± 13, P =0.003).
Conclusion: In this case–control study with propensity matching, clinician use of closed-loop assistance resulted in a
greater portion of case time spent in a preload-independent state throughout surgery compared with manual delivery
of goal-directed fluid therapy.
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Goal-directed fluid therapy (GDFT) strategies based on
cardiac output (CO) optimization have been shown to
benefit moderate- to high-risk surgery patients [1-5] and
have recently been recommended by professional societies
in the United Kingdom [6], France [7] and Europe [8].
However, despite the growing evidence, these strategies
are often not implemented in current practice [9]. One of
the reasons for this lack of implementation is that GDFT
strategies, like any other complex clinical protocol, require
significant provider attention and vigilance for consistent
implementation, and it is well known that, even under
study conditions, protocol compliance rates are often not
greater than 50% [10-12].
Computer systems excel at repetitive, “attention-based”
tasks and do not suffer from vigilance decrement [13]. For
this reason, closed-loop (automated) systems frequently
exhibit higher accuracy than clinicians in maintaining a
target set point [14], and they have the added benefit of
reducing overall provider workload instead of adding to it
[15]. On the other hand, choosing target set points, or even
deciding whether to apply a given clinical protocol to a
given patient, is still a judgment-based decision that
computer systems are not well suited for. These decisions
remain the domain of physicians and other clinical care
providers [16]. Ideally, computer-based implementation
systems applied under the direction of clinicians could
achieve clinical aims by assisting clinicians with the “busy
work” of protocol implementation while leaving direction
and guidance in the hands of the care providers.
Over the past 4 years, we have developed a closed-loop
fluid delivery system designed to assist anesthesia pro-
viders with GDFT strategies. The system has been tested
extensively in simulation [17,18], engineering studies [19],
animal studies [20] and a pilot clinical trial [21]. The aim
of the present study was to assess the closed-loop system
in a moderate- to high-risk surgical cohort and compare
that cohort to matched patients who received manual
GDFT. Based on our background research, our hypothesis
was that the patients receiving closed-loop assistance
would spend more time in a preload-independent state,
defined as percentage of case time with stroke volume
variation (SVV) less than or equal to 12% [21].
Materials and methods
Enrollment
This study was approved by the University of California
Irvine (UCI) Institutional Review Board (IRB) (HS 2011-
8554) and registered with ClinicalTrials.gov (protocol ID
NCT02020863). The study was conducted at UCI Medical
Center in Orange, CA, USA, from September 2013
through February 2014. Patients eligible for the study were
all those over 18 years of age scheduled for hepatobiliary,
pancreatic or splenic surgery and expected to receiveintravascular arterial blood pressure monitoring as part of
their anesthetic care. Exclusion criteria were under
18 years of age, pregnant, body mass index >35 kg/m2,
presence of moderate to severe valvular disease, cardiac
arrhythmias, left ventricular ejection fraction <40% and
right ventricular failure. Additionally, any patients who
were found to have metastatic disease during a laparoscopic
examination and who had their primary procedures aborted
as a result were excluded. Patients were recruited on days
when a member of the study group was available to consent
and the research staff was available to set up the
closed-loop system. In general, this was about 30% of
the time during the study period.
As a stipulation of the IRB approval, none of the
investigators were permitted to be part of the primary
anesthesia team for study cases. All patients included in
the study were given details of the project verbally and
in writing by a member of the study group, and then
they provided written informed consent if willing to
participate. The results of this study are reported according
to the Strengthening the Reporting of Observational
Studies in Epidemiology guidelines [22].
Study protocol
All of the subjects were patients of one of two surgeons
who use similar preoperative preparation protocols
(clear fluids only the day before surgery). Bowel preps
were not performed in any of the subjects, and all
patients followed a strict nothing per os after midnight
policy for the day of surgery.
Anesthesia was induced with fentanyl (2 μg/kg) and pro-
pofol (2 to 3 mg/kg). Following induction, rocuronium
was administered to facilitate intubation. Anesthesia was
maintained with sevoflurane and fentanyl boluses at the
discretion of the anesthesia team. All patients were
mechanically ventilated using a volume control mode
with tidal volume at 8 ml/kg of ideal body weight and
respiratory rate adjusted to achieve an end-tidal CO2
between 32 and 36 cmH2O. Any necessary adjustments to
anesthetic delivery were made at the discretion of the
primary anesthesia providers.
All subjects had invasive arterial pressure monitoring
via the radial artery planned as part of their anesthetic
care. Standard practice in our institution for moderate- to
high-risk hepatobiliary surgery patients is to use flow-based
monitoring that includes a dynamic predictor of fluid
responsiveness such as SVV to provide GDFT. For these
cases (both study and control group), all patients were
monitored with one of three dedicated EV-1000 monitors
and a FloTrac sensor (Edwards Lifesciences, Irvine,
CA, USA).
Finally, all patients except those undergoing liver
resection had a thoracic epidural placed by the pain
service in the preoperative holding area prior to coming
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(save for a 3-ml test dose of 2% lidocaine with 1:200,000
epinephrine) until the surgical case was closing and emer-
gence of the patient was beginning (and data collection
completed).
Closed-loop setup
The closed-loop software (Sironis, Newport Beach, CA,
USA) was run on a Shuttle X50 Touchscreen PC (Shuttle
Computer Group, City of Industry, CA, USA) running
Windows 7 (Microsoft, Redmond, WA, USA). The system
was connected via a USB to serial adapter to the serial
output port of the EV-1000 for real-time capture of data.
A Q Core Sapphire Multi-Therapy Infusion Pump
(Q Core Medical, Netanya, Israel) was used by the
closed loop to deliver fluid. The Sapphire pump is a
single-channel volumetric pump capable of flow rates
from 0.1 to 999 ml per hour. The pump was controlled by
the closed-loop system using software provided by Q Core
via serial connection (Commands Server R.00).
Following placement of the arterial line (and central line
if applicable), but before surgical start time, the closed-
loop system target was selected by the primary anesthesia
team (scaled stroke volume (SV) increase of 7.5% to 22.5%
over 500 ml, standard setting 15%) and started. The pri-
mary team was responsible for selection of therapy targets
throughout the case (see below in Closed-Loop System
Description).
Closed-loop system description
The closed-loop system has been described extensively
in previous publications [17-21]. Briefly, the system
monitors SV, heart rate (HR), mean arterial pressure
(MAP) and a dynamic predictor of fluid responsiveness
such as pulse pressure variation or SVV and uses this
information to optimize SV in line with a GDFT protocol.
The controller uses both a model layer to formulate a
predicted response to a fluid bolus and an adaptive
layer for bolus-based error correction during direct
fluid management to correct for changes induced by
surgical and anesthetic conditions. The final action to
be taken by the controller is then determined by a
rule-based layer based on data provided by the previous
layers [19]. The system is ultimately a slope-seeking
controller whose aim is to optimize patients’ fluid status
and SV to near the plateau of the Frank–Starling
curve. The system delivers 100-ml fluid boluses over
the course of 6 minutes when indicated (maximum
rate =1,000 ml/hour) and is therefore designed not for
high-volume resuscitation, but rather for hemodynamic
optimization in line with GDFT protocols.
The exact point on the Frank–Starling curve to be
targeted by the controller can be adjusted by the primary
anesthesiologist by adjusting the target SV increase,allowing providers to make fluid therapy more liberal
or more conservative as appropriate while still following a
GDFT protocol. Additionally, the primary anesthesia team
can put the system on standby (monitor-only mode),
deliver a fluid challenge manually or deliver continuous
fluid in the case of an emergency.
The primary anesthesiologist was aware of each bolus
of fluid administered by the closed-loop system throughout
the surgical procedure. This was done through visual and
audio signals alerting the clinician that a fluid bolus was
initiated. Additionally, the closed-loop system requires the
primary care provider to input the amount of fluid
available for delivery, and this volume is limited to 500 ml
at a time. This feature was specifically designed as another
safety check, as it requires the supervising anesthesiologist
to “reauthorize” the system to deliver fluid in 500-ml
increments, ensuring the system cannot deliver more
than this volume at any time without the supervisor
being aware of it. Lower volumes could be chosen at
the supervisor’s discretion (200 ml or even 100 ml).
Fluid administration protocol
In the standard GDFT patients treated at UCI Medical
Center, a 3 ml/kg/hr baseline crystalloid infusion is run,
and providers follow the protocol shown in Figure 1 by
hand [23]. For the closed-loop cases, patients received
a restrictive baseline isotonic crystalloid infusion of
3 ml/kg/hr on a pump throughout the duration of the
case as maintenance fluid. In addition to the baseline crys-
talloid, the closed-loop system administered colloids chosen
by the primary anesthesia team. Available fluids were 6%
hydroxyethyl starch 130/0.4 (Voluven; Fresenius Kabi,
Frankfurt, Germany) or 5% serum albumin (Grifols, Sant
Cugat del Vallès, Spain). The anesthesia provider had the
option of stopping a bolus (or initiating one) if he or she
disagreed with the closed-loop fluid management system,
and these events were recorded by the system. If the pri-
mary anesthesia team felt the patient was fluid-optimized
but the patient’s systolic blood pressure was still 20% or
more below baseline value (despite appropriate anesthetic
depth), they were to consider an inotrope or vasopressor
per the lower portion of the manual protocol (Figure 1).
Case matching
Following completion of enrollment, each study patient
was matched to a non–closed-loop assisted patient
treated during the same time period using a propensity
score match to reduce bias [24,25] (Figure 2). The pro-
pensity score was estimated using logistic regression to
regress group assignment on the predictors in Table 1
(age, height, weight, sex, HR, Stroke Volume Index
(SVI), MAP, SVV, specific scheduled procedure and
surgeon). Each study patient was then matched 1:1 to a
control case using calipers of 0.04% width (20% of the
Figure 1 Manual goal-directed fluid therapy protocol. The
protocol that anesthesia providers utilize in moderate- and high-risk
surgery cases at University of California Irvine Medical Center and
that was applied to the patients in the manual group. C.I., Cardiac
index; IBW, Ideal body weight; SV, Stroke volume; SVV, Stroke
volume variation.
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a control manual GDFT (M) group to compare with the
closed-loop assisted (CL) group. The complete propensity
match process, data table and matched pairs are detailed
in Additional file 1.
Outcomes, data collection and analysis
The following data were collected continuously at
60-second intervals for each patient by the anesthesia
information management system (AIMS) (Surgical
Information Systems, Alpharetta, GA, USA): HR, MAP,
SV, CO and SVV. Fluid volume, urine output, blood loss,
and vasopressors were also recorded in the AIMS by the
primary anesthesia team. In study cases, the closed-loop
controller also recorded continuous hemodynamic data
(HR, MAP, SV and SVV) provided by the EV-1000 at
2-second intervals, as well as fluid administration andprovider interactions (set point changes, bolus stops
and test boluses administered).
Baseline values for HR and MAP were taken from the
preoperative anesthesia assessment. Baseline values for
SVI and Cardiac Index (CI) were taken as the mean of
the first minute’s recording 5 minutes after placement of
the arterial line and calibration of the hemodynamic
monitoring system. Mean case value for each hemodynamic
variable was calculated as the average value of all recordings
between baseline and the beginning of surgical closure.
Final case value for each hemodynamic variable was defined
as the average value of each parameter over the last minute
before the beginning of emergence (lowering of anesthetic
agent in preparation for extubation). Finally, a Postoperative
Morbidity Survey (POMS) score [26] was calculated for
each patient, and length of Surgical Intensive Care Unit
(SICU) and hospital stay were recorded.
The primary outcome between groups was GDFT
compliance, defined as percentage of case time where
SVV was ≤12%. Upon study initiation in September 2012,
the original endpoint was cardiac SV. When our case
series in Europe was finished, informal comparison with
other standard case data showed strong effects on SVV
for the CL group, but weaker effects on SV itself [21].
Moreover, we observed that SVI as recorded by the
minimally invasive CO monitoring systems has a very
wide distribution between and within patients [27,28],
meaning a large sample size would be needed to
detect true effects on this variable. Second, Pearse and
colleagues reported the full “Optimisation of peri-operative
cardiovascular management to improve surgical outcome”
(OPTIMISE; ISRCTN04386758) study in 2014 [5]. One of
the findings of that study was the importance of protocol
compliance to the beneficial effects of the GDT:
In the prespecified adherence-adjusted analysis
conducted using established methods [citation omitted],
the observed treatment effect was strengthened when
the 65 patients whose care was nonadherent [internal
cross-reference omitted] were assumed to experience
the same outcome as if they had been allocated to the
alternative group (RR, 0.80; 95% CI, 0.61-0.99; P = .04).
(p 2186 [5])
On the basis of the pilot study data, the findings
derived from the OPTIMISE trial and the fact that it
would be the same endpoint as the pilot study (GDFT
protocol compliance), we decided to treat protocol
compliance measured as SVV as the primary outcome
measure in the present study.
Secondary endpoints were case mean hemodynamic
values, final case hemodynamic values, fluid volumes,
urine output, postoperative complications, SICU length
of stay and hospital length of stay. Additional measures
Figure 2 Recruitment and case-matching process. Potential subjects were recruited throughout the study period. At the end of recruitment,
and after excluding five cases due to aborted procedures or decision to proceed without an arterial line, there were thirty-five study cases in the
closed-loop assisted group. During the same time period, 60 other patients who met the inclusion criteria received manual goal-directed fluid
therapy (GDFT). All 35 study patients and 60 manual group patients were run in a propensity match process, after which each closed-loop assisted
patient was matched to the closest possible manual patient, leaving 35 patients in each group. ASA, American Society of Anesthesiologists Physical
Status patient classification; HR, Heart rate; MAP, Mean arterial pressure; SVI, Stroke Volume Index.
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were distribution of fluid boluses given across cases
(minimum, maximum, mean and SD), percentage of the
boluses that resulted in an SV increase and predictive
specificity as number of fluid boluses given to a patient
increased. Provider interactions with the system were
also recorded (start and stop of boluses and changes in
controller set point).
Based on local data, case time with SVV ≤12 in the
case types to be studied was approximately 80 ± 10%
over the previous 1-year period, or about 20 ± 10% non-
compliance time. Cutting non-compliance time in half
(or more) was considered a clinically relevant endpoint
that, assuming a power of 0.8 and a significance level of
0.05, would require 21 patients in each group to be ad-
equately powered.
Continuous scalar data were tested for normality using
a Kolmogorov–Smirnov test. If normal, the data are re-
ported as mean ± SD and comparisons were made usingStudent’s t-test. Non-normally distributed scalar data
and ordinal data (namely, POMS scores) are reported as
median (25th, 75th percentile), and comparisons were
made with the Mann–Whitney U test. The significance
level for the primary outcome was set at 0.05. All other
comparisons were made at the 0.025 level to compensate
for the multiple secondary endpoints.
Results
Enrollment and case matching
Forty patients were enrolled in the study over the study
period, out of a total of one hundred one patients who
met the eligibility criteria. Four were excluded when sur-
gery was aborted because of discovery of metastatic dis-
ease on initial laparoscopic examination, and one patient
was excluded because the primary team chose not to
place an arterial line after enrollment.
The remaining 35 patients were matched 1:1 against
the control patients using the propensity score. Of the
Table 1 Demographics and baseline hemodynamic data after propensity matcha
Parameter Manual Closed-loop assisted Absolute standardized difference (%)*
Age (yr) 61.5 ± 11.4 61.6 ± 12.8 1.3
Height (cm) 166 ± 10 166 ± 12 3.5
Weight (kg) 73.9 ± 17.5 73.9 ± 23.7 0.2
Sex
Male 11 11 0.0
Female 14 14
Specific surgical procedure
Whipple 6 6 0.0
Whipple + additional 6 6
Distal pancreatectomy 3 3
Liver resection 8 8
Complex cholecystectomy 2 2
ASA Physical Status patient classification




Heart rate (bpm) 72 ± 12 73 ± 10 7.0
Mean arterial pressure (mmHg) 88 ± 11 88 ± 10 5.5
Stroke Volume Index 44 ± 12 44 ± 10 1.2
Cardiac Index 3.1 ± 0.9 3.1 ± 0.8 4.8
abpm, Beats per minute. Data are expressed as mean ± standard deviation for scalar data or as counts for categorical data. * Absolute standardized difference
>10% is considered a significant imbalance in matching.
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have CO monitoring during their procedures, leaving 55
completed controls that were performed during the same
time period. A total of 25 matched pairs were found within
the predefined caliper distance. Demographic data for the
two groups, as well as baseline hemodynamic values
(HR, SVI and MAP) and specific procedure distribution,
are shown in Table 1. Absolute standardized distance for
each match parameter was <10%, suggesting the propensity
score matching process was effective in selecting a control
group similar to the study group at baseline [29].
Case variables
There was no significant difference in case time, estimated
blood loss (EBL), urine output (UO), total crystalloid
administration, total colloid administration, crystalloid
measured as milligrams per kilogram per hour, colloid
as milligrams per kilogram per hour, transfusion rates or
administration of cardiovascular support agents (Table 2)
between groups.
Primary outcome
The CL group spent a significantly higher portion of case
time in a preload-independent state. The average CL patient
spent 95 ± 6% of the case time with an SVV ≤12%, whereasthe average M group patient spent 87 ± 14% of the case
time in this range (P =0.008). Both of these rates
were significantly higher than the general rate recorded in
the previous year (80%). Box plots for compliance in both
groups are shown in Figure 3.
Secondary outcomes
The CL group had a significantly lower case mean SVV
compared with the M group (7.7 ± 12 versus 8.8 ± 2.5,
P =0.003). There was no significant difference in case
mean HR, SVI, CI, MAP or SVI, though there was a
trend toward lower HR in the CL group (non-significant
at P =0.035 because of the significance level adjustment
for multiple outcomes). The CL group also had a
lower final SVV (6.9 ± 3.4 versus 9.2 ± 3.1, P =0.015)
and a lower final HR compared with the M group
(77 ± 12 versus 88 ± 13, P =0.003). There was no signifi-
cant difference in final CI, MAP or systemic vascular
resistance between groups.
There were no significant differences in length of
SICU stay, total hospital stay, postoperative day 3 POMS
score or postoperative day 5 POMS score. Case variables,
hemodynamic data, length of stay data and POMS scores
are all shown in Table 2. Principal hemodynamic variables
for all cases are graphed in Figure 4.
Table 2 Hemodynamic and case dataa
Manual Closed-loop P-value
Case time (min) 472 (346, 571) 433 (324, 583) 0.467
Estimated blood loss (ml) 200 (50, 400) 100 (25, 250) 0.182
Urine output (ml) 525 (345, 705) 625 (300, 900) 0.491
Total crystalloid (ml) 2500 (1,567, 3,817) 2100 (1,554, 3,653) 0.628
Crystalloid (ml/kg/hr) 4.9 (3.6, 6.4) 4.6 (3.5, 6.8) 0.977
Total colloid (ml) 750 (375, 1,050) 576 (400, 1,199) 0.938
Colloid (ml/kg/hr) 1.4 (0.7, 1.7) 1.4 (0.8, 1.6) 0.634
Blood (U/case) 0 (0, 0) 0 (0, 0) 0.760
Phenylephrine (μg) 300 (50, 700) 200 (0, 500) 0.480
Ephedrine (mg) 10 (5, 25) 10 (0, 20) 0.510
Length of SICU stay (d) 1 (0, 1) 0 (0, 2) 0.648
Length of hospital stay (d) 6 (4, 7) 6 (3, 9) 0.652
Total length of stay (d) 7 (5, 8) 6 (4, 11) 0.815
Mean HR (bpm) 78 ± 10 72 ± 10 0.035
Mean SVI (ml/m2) 43 ± 9 45 ± 10 0.615
Mean CI (L/m2/min) 3.5 ± 0.8 3.3 ± 0.8 0.373
Mean MAP (mmHg) 83 ± 9 79 ± 8 0.077
Mean SVR (dyn · s/cm5) 1070 ± 302 1121 ± 353 0.580
Mean SVV (%) 8.8 ± 2.5 7.0 ± 1.2 0.003†
End HR (bpm) 88 ± 13 77 ± 10 0.003†
End SVI (ml/m2) 42 ± 11 45 ± 11 0.308
End CI (L/m2/min) 3.4 ± 1.1 3.4 ± 0.9 0.811
End MAP (mmHg) 82 ± 13 78 ± 19 0.411
End SVR (dyn · s/cm5) 1042 ± 336 1033 ± 315 0.926
End SVV (%) 9.2 ± 3.1 6.9 ± 3.4 0.015*
POMS score
Postoperative day 3 3 (2,4) 3 (2,4) 0.683
Postoperative day 5 1 (1,3) 2 (1,3) 0.408
abpm, Beats per minute; CI, Cardiac Index; HR, Heart rate; MAP, Mean arterial pressure; POMS, Postoperative Morbidity Survey; SICU, Surgical Intensive Care Unit; SVR,
Systemic vascular resistance; SVI, Stroke Volume Index; SVV, Stroke volume variation. Data are presented as mean ± standard deviation for normally distributed scalar data,
or as median (25th, 75th percentiles) for non-normally distributed scalar or ordinal data. *Primary outcome tested at P <0.05. †Secondary outcome tested at P <0.025.
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The closed-loop system gave a total of 214 discrete 100-ml
fluid boluses across the 25 study cases, with an average of
8.5 ± 6.5 boluses per case. The minimum given in a case
was one bolus, and the maximum was twenty-six. Of the
214 fluid boluses given by the controller, 137 resulted in a
scaled cardiac SV increase of at least 15% over 500 ml, and
124 resulted in a scaled SV increase of at least 10% over
250 ml. No comparison data are available for the control
group, as individual fluid boluses were not recorded by the
providers in the AIMS.
The controller’s predictive specificity improved with
increased experience with the patients. The first to third
fluid boluses given to patients had a mean scaled SVI in-
crease of 10.2 ± 43%, the fourth to seventh 12 ± 36% and
the eight and later 18 ± 35%.In terms of interactions with the closed-loop system,
providers delivered 18 fluid boluses through the closed-
loop system by hand. The mean scaled SVI increase
following provider boluses was 6.8 ± 28.4%, and the mean
scaled increase following system boluses was 14 ± 29%,
though this difference was non-significant due to the
wide ranges.
Thirty-four fluid boluses that the system initiated
were halted by providers before or during delivery.
None of the providers put the system into a con-
tinuous infusion mode during use. In terms of the
system targets, across all cases, the system was set
to use the default 15% SV increase target for 92% of
case time. It was set to 11% (more liberal) 4.5% of
the time, and 3.5% of the time it was set to 19%
(more conservative). The system was never set to
Figure 3 Hemodynamics for the first 5 hours of all cases. Each graph is an overlay of all 25 patients in the group. Only the first 300 minutes
of cases (if longer than 5 hours) are shown.
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Figure 4 Goal-directed fluid therapy compliance by group. Box
plots for the manual and closed-loop assisted groups, including
outliers, are shown. The closed-loop assistance not only improved
mean compliance to goal-directed fluid therapy (GDT) principles but
also substantially reduced the variability in compliance within the group
(manual group compliance standard deviation (SD) =14%, closed-loop
group compliance SD =6%). Asterisks represent outliers, dot represent
extreme outliers.
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able range.
Discussion
In this article, we report the first comparison of a closed-
loop fluid administration system to assist clinicians in
providing GDFT versus manual GDFT application in
surgical patients. The 25-patient cohort was compared with
a propensity score-matched control group and was found
to have spent a significantly greater portion of the case time
in a preload-independent state (case time with SVV ≤12%)
and to have a lower mean HR throughout surgery. There
were no significant differences in fluid administration
volume, EBL or other case variables between groups.
This trial is the first in which the quality of GDFT delivery
by the closed-loop system has been tested in a true clinical
environment. Moreover, the system was compared with a
provider cohort well-versed in GDFT principles, having had
a clinical protocol in place since 2011 mandating use
of advanced hemodynamic monitoring and SV optimization
in hepatobiliary surgery and hosting an annual conference
focusing on GDFT principles.
The finding that the CL group spent more of the case
time with cardiac SV in a preload-independent state
(and with a lower average HR) suggests that this group
was well-resuscitated in terms of intravascular volume.
One would expect this to be readily accomplished simply
by heavily volume-loading patients. In this study, however,
and in contrast to the differences in SVV and HR, fluid
administration volumes were virtually identical between
groups, as was EBL. Given the absence of any otherobvious baseline or case difference to explain the SVV dif-
ference between the groups (Tables 1 and 2), this differ-
ence seems most likely to be a result of the timing of fluid
administration. This finding may have been predicted by
our previous simulation and animal studies [17,20] in
which similar results were found to arise from differences
in timing of administration between groups.
The CI in both groups increased by about 10% over
the duration of the cases, likely as a response to the
physiologic stress of surgery. In the CL group, this
increase occurred through a combination of HR and SV
increases (Tables 1 and 2), whereas in the M group, the
CI increase resulted more from the HR increase alone.
The mean SVI in the M group was actually lower at the
end of the cases than at the beginning, whereas in the
CL group, it increased modestly throughout, though
these differences were not statistically significant.
On the basis of the results of this initial study, the
closed-loop system may benefit surgical care in several
ways. First, use of the closed-loop system should provide
high-quality implementation of GDFT with minimal
additional clinician workload compared with non-GDFT
practice. From a quality assurance standpoint, the closed-
loop system could also help standardize GDFT delivery
across providers and even institutions. Finally, if the system
is shown to reduce overall provider “tasks” with regard to
fluid therapy (for example, starting a bolus, calculating
change in SV or tracking fluid delivered), this would free
up time and attention to focus on higher-level care factors.
This study provides the first clinical evidence that this
closed-loop fluid administration system can assist clinicians
in providing, and even improving, the quality of GDFT. A
number of important study questions remain. Validation of
these results at other centers and in randomized studies are
warranted, as are studies in other types of surgical cases.
Comparison of the closed-loop assistance in this study was
to standard hand-provided GDFT; comparison to other
fluid management strategies, especially in institutions with-
out guidelines, would be valuable. Moreover, studies of pro-
vider workload with versus without the closed-loop system
could also be informative, as would other studies specifically
looking at patient outcomes in the postoperative period. Fi-
nally, the potential for applications outside the intraopera-
tive period (for example, in the SICU) could be investigated.
Limitations
There are several limitations of the present study that
warrant discussion. The most obvious limitation of the
study is that it was not randomized, and the case matching
may have failed to correct an unrecognized bias in one of
the groups. The use of the propensity matching method
(versus a standard case match based on a small subset
of variables) was one attempt to control for this pos-
sibility, and, although the baseline group data suggest
Rinehart et al. Critical Care  (2015) 19:94 Page 10 of 11that the groups were indeed similar on the compared
characteristics, the potential for bias cannot be completely
eliminated.
With regard to the regression done for the propen-
sity score, it is possible that, although patients with
moderate to severe cardiac disease were excluded
from the study, baseline differences existed between
the study and control groups, and these were not
accounted for in the model. Also, the presence of the
research team and closed-loop system in the study
group may have led to behavioral changes among the
primary anesthesia care team that may have affected
outcomes.
CO and SV were measured from a peripheral arterial
line, a technology with known limitations. Both groups
used the same monitoring system, however, and, given
the declining use of Swan-Ganz catheters in general
practice, the majority of GDFT worldwide is being
applied via the same or comparable devices. The highly
accessible nature of minimally invasive CO monitoring
was a large part of what made intraoperative closed-loop
GDFT feasible in the first place [30].
Finally, arterial line dampening is checked for within
the closed-loop algorithm, and an alert is issued to the
supervisor if dampening is suspected. Arterial line
dampening was not independently checked for in the
control patients; this was dependent on the managing
anesthesiologist. If arterial line dampening occurred and
went uncorrected for a significant portion of case time,
this may have affected results.
Conclusions
In this case–control study with propensity matching,
clinician use of closed-loop assistance resulted in a
greater portion of case time spent in a preload-
independent state throughout surgery compared with
manual delivery of GDFT, as well as a lower final
HR as compared with manual administration. SVI,
MAP and cardiac index were not significantly different
between groups.
Key messages
 Closed-loop assistance with intraoperative
goal-directed fluid therapy resulted in greater case
time with patients in a preload-independent state.
 There were no significant differences in fluid
administration volume between groups.
 The closed-loop hemodynamic optimization and
fluid management required minimal provider
supervision after therapy targets were set.
 Closed-loop hemodynamic optimization and fluid
management may enable consistent adherence to
perioperative goal-directed therapy protocols.Additional file
Additional file 1: Detailed description of propensity matching
process as well as raw matching table and data.
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